Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 5/20 | 0.72 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636228 | 0.89 | KAT2B (0.69) | KAT2BHCAR3MAPTALDH1A1TDP1 | |
| SCHEMBL14906561 | 0.88 | KAT2B (0.74) | KAT2BHCAR3MAPTALDH1A1TDP1 | |
| SCHEMBL16151564 | 0.87 | KAT2B (0.72) | KAT2BHCAR3MAPTALDH1A1TDP1 | |
| SCHEMBL14981759 | 0.85 | KAT2B (0.97) | KAT2BMAPTPKMCYP3A4TSHR | |
| SCHEMBL8976381 | 0.85 | KAT2B (0.57) | KAT2BHCAR3MAPTALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL513348 | 0.84 | KAT2B (1.00) | KAT2BMAPTPOLBPKMCYP3A4 | |
| Bromide SCHEMBL8619139 | 0.84 | KAT2B (0.56) | KAT2BHCAR3MAPTALDH1A1TDP1 | |
| SCHEMBL8313477 | 0.83 | KAT2B (0.69) | KAT2BMAPTALDH1A1TDP1L3MBTL1 | |
| SCHEMBL7767318 | 0.83 | MAPT (0.62) | KAT2BHCAR3MAPTALDH1A1TDP1 | |
| SCHEMBL981242 | 0.83 | KAT2B (0.64) | KAT2BHCAR3MAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | KAT2B 3645/4885HCAR3 152/4885MAPT 323/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | KAT2B 3645/4885HCAR3 152/4885MAPT 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.